-+ 0.00%
-+ 0.00%
-+ 0.00%

BioLineRx Starts Fourth Cohort in Phase 1/2a Trial of GLIX1 for High-Grade Glioma

PUBT·11/16/2026 12:06:09
Listen to the news
BioLineRx Starts Fourth Cohort in Phase 1/2a Trial of GLIX1 for High-Grade Glioma
  • BioLineRx and Hemispherian presented GLIX1 clinical trial updates and preclinical findings at the 2026 Society for Neuro-Oncology annual meeting.
  • The Phase 1/2a high-grade glioma trial began dosing its fourth cohort, with no significant treatment-emergent adverse events observed.
  • Clinical results are expected in the first half of 2027.
  • Preclinical studies showed brain penetration and antitumor activity across glioblastoma models, including disease resistant to temozolomide.
  • Remaining trial cohorts will include patients whose tumor tissue can be assessed directly for brain penetration and biological activity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLineRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611160700PR_NEWS_USPR_____IO98046) on November 16, 2026, and is solely responsible for the information contained therein.